Key Insights

Highlights

Success Rate

93% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

4.8%

1 terminated out of 21 trials

Success Rate

93.3%

+6.8% vs benchmark

Late-Stage Pipeline

10%

2 trials in Phase 3/4

Results Transparency

21%

3 of 14 completed with results

Key Signals

3 with results93% success

Data Visualizations

Phase Distribution

11Total
Not Applicable (1)
P 1 (2)
P 2 (6)
P 3 (2)

Trial Status

Completed14
Recruiting3
Active Not Recruiting2
Terminated1
Withdrawn1

Trial Success Rate

93.3%

Benchmark: 86.5%

Based on 14 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT04976036Phase 2RecruitingPrimary

Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients

NCT04108052Not ApplicableCompletedPrimary

Diagnostic Value of Ultra-low Dose Thoracic Scanner for the Pulmonary Arteriovenous Malformation Detection in HHT Patient

NCT02484716Phase 2CompletedPrimary

Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)

NCT03227263Phase 3Completed

BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).

NCT03954782Phase 2CompletedPrimary

Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.

NCT02157987Phase 1CompletedPrimary

Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose

NCT05933330Active Not RecruitingPrimary

Hereditary Hemorrhagic Telangiectasia and Neurovascular Manifestations, in the Danish HHT Database

NCT03910244Phase 2CompletedPrimary

Pomalidomide for the Treatment of Bleeding in HHT

NCT00230672CompletedPrimary

Investigation of Plasma Proteins in Patients With Hereditary Haemorrhagic Telangiectasia and PAVMs

NCT00230685RecruitingPrimary

Case Notes Review on Patients With Hereditary Haemorrhagic Telangiectasia

NCT00230620RecruitingPrimary

Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families

NCT00230659CompletedPrimary

Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia

NCT00733655CompletedPrimary

Study of Histological Samples From Patients With Hereditary Haemorrhagic Telangiectasia

NCT00230633Active Not RecruitingPrimary

Studies of White Blood Cells Derived From HHT Patients

NCT01507480Phase 1Completed

The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia

NCT00684879Completed

Screening Behavior in Adults With Hereditary Hemorrhagic Telangiectasia

NCT00733629WithdrawnPrimary

Study of Endothelial Cells in Patients With Hereditary Haemorrhagic Telangiectasia

NCT00355108Phase 3CompletedPrimary

ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome

NCT01408030Phase 2CompletedPrimary

North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

NCT02204371Phase 2TerminatedPrimary

Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia

Scroll to load more

Research Network

Activity Timeline